Exploring the significance of glycosylation in prostate cancer subtyping through single-cell analysis

Prostate cancer impacts millions of men worldwide and causes significant disease burden. Glycosylation is the post-translational modification offering novel therapeutics for prostate cancer. The scRNA-seq data is combined with bulk RNA-seq data of prostate cancer to understand the glycosylation role and identify the therapeutic targets. This study aims to investigate the differences within tumor and the role of glycosylation. The findings confirm that glycosylation can establish multiple cell biomarkers and divide the cell subtypes of prostate cancer. The specific cell subtypes have diverse functions in cell interactions, transcript activity, prognosis and immunotherapy response, such as UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7+ (GALNT7+) epithelial cells and UDP Glucose Ceramide Glucosyltransferase+ (UGCG+) cancer associated macrophages. These outcomes assist in the better understanding of prostate cancer and provide new approach of the targeted therapy.

Prostate cancer; Glycosylation; Single-cell analysis; Subtyping

[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022; 72: 7–33.

[2] Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. The Lancet. 2021; 398: 1075–1090.

[3] Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Annals of Oncology. 2018; 29: 1807–1813.

[4] Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. Journal of Clinical Oncology. 2020; 38: 395–405.

[5] Smith BAH, Bertozzi CR. The clinical impact of glycobiology: targeting selectins, siglecs and mammalian glycans. Nature Reviews Drug Discovery. 2021; 20: 217–243.

[6] Berger M, Kaup M, Blanchard V. Protein glycosylation and its impact on biotechnology. Genomics and Systems Biology of Mammalian Cell Culture. 2011; 28: 165–185.

[7] Copoiu L, Malhotra S. The current structural glycome landscape and emerging technologies. Current Opinion in Structural Biology. 2020; 62: 132–139.

[8] Trbojević-Akmačić I, Lageveen-Kammeijer GSM, Heijs B, Petrović T, Deriš H, Wuhrer M, et al. High-throughput glycomic methods. Chemical Reviews. 2022; 122: 15865–15913.

[9] Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nature Reviews Cancer. 2015; 15: 540–555.

[10] Mehboob MZ, Lang M. Structure, function, and pathology of protein O-glucosyltransferases. Cell Death & Disease. 2021; 12: 71.

[11] Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nature Reviews Nephrology. 2019; 15: 346–366.

[12] Kaluza A, Szczykutowicz J, Ferens-Sieczkowska M. Glycosylation: rising potential for prostate cancer evaluation. Cancers. 2021; 13: 3726.

[13] Gilgunn S, Murphy K, Stöckmann H, Conroy PJ, Murphy TB, Watson RW, et al. Glycosylation in indolent, significant and aggressive prostate cancer by automated high-throughput n-glycan profiling. International Journal of Molecular Sciences. 2020; 21: 9233.

[14] Scott E, Munkley J. Glycans as biomarkers in prostate cancer. International Journal of Molecular Sciences. 2019; 20: 1389.

[15] Xu Y, Gao Z, Hu R, Wang Y, Wang Y, Su Z, et al. PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy. Journal for ImmunoTherapy of Cancer. 2021; 9: e002699.

[16] Shi C, Wang Y, Wu M, Chen Y, Liu F, Shen Z, et al. Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation. Nature Communications. 2022; 13: 6951.

[17] Adeva-Andany M, Pérez-Felpete N, Fernández-Fernández C, Donapetry-García C, Pazos-García C. Liver glucose metabolism in humans. Bioscience Reports. 2016; 36: e00416.

[18] Li Y, Lin Y, Aye L, Dong L, Zhang C, Chen F, et al. An integrative pan‐cancer analysis of the molecular and biological features of glycosyltransferases. Clinical and Translational Medicine. 2022; 12: e872.

[19] Lairson LL, Henrissat B, Davies GJ, Withers SG. Glycosyltransferases: structures, functions, and mechanisms. Annual Review of Biochemistry. 2008; 77: 521–555.

[20] Saha A, Bello D, Fernandez-Tejada A. Advances in chemical probing of protein O-GlcNAc glycosylation: structural role and molecular mechanisms. Chemical Society Reviews. 2021; 50: 10451–10485.

[21] Wu Y, Yang S, Ma J, Chen Z, Song G, Rao D, et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discovery. 2022; 12: 134–153.

[22] Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, et al. Inference and analysis of cell-cell communication using CellChat. Nature Communications. 2021; 12: 1088.

[23] Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics. 2010; 11: 367.

[24] Aibar S, González-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G, et al. SCENIC: single-cell regulatory network inference and clustering. Nature Methods. 2017; 14: 1083–1086.

[25] Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics. 2013; 14: 7.

[26] Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang P, et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Medicine. 2020; 12: 21.

[27] Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nature Medicine. 2018; 24: 1550–1558.

[28] Gao X, Moriyama S, Miura N, Dean N, Nishimura S. Interaction between the C termini of Alg13 and Alg14 mediates formation of the active UDP-N-acetylglucosamine transferase complex. Journal of Biological Chemistry. 2008; 283: 32534–32541.

[29] Averbeck N, Gao X, Nishimura S, Dean N. Alg13p, the catalytic subunit of the endoplasmic reticulum UDP-GlcNAc glycosyltransferase, is a target for proteasomal degradation. Molecular Biology of the Cell. 2008; 19: 2169–2178.

[30] Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A, et al. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene. 2023; 42: 926–937.

[31] Masone MC. The role of GALNT7 as a potential diagnostic marker in prostate cancer. Nature Reviews Urology. 2023; 20: 198.

[32] Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H. Global view of human protein glycosylation pathways and functions. Nature Reviews Molecular Cell Biology. 2020; 21: 729–749.

[33] Jain V, Harper SL, Versace AM, Fingerman D, Brown GS, Bhardwaj M, et al. Targeting UGCG overcomes resistance to lysosomal autophagy inhibition. Cancer Discovery. 2023; 13: 454–473.

[34] Bolik J, Krause F, Stevanovic M, Gandraß M, Thomsen I, Schacht S, et al. Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis. Journal of Experimental Medicine. 2022; 219: e20201039.

[35] Christofides A, Strauss L, Yeo A, Cao C, Charest A, Boussiotis VA. The complex role of tumor-infiltrating macrophages. Nature Immunology. 2022; 23: 1148–1156.

[36] Huo J, Ren S, Gao P, Wan D, Rong S, Li X, et al. ALG13 participates in epileptogenesis via regulation of GABAA receptors in mouse models. Cell Death Discovery. 2020; 6: 87.

[37] Ng BG, Eklund EA, Shiryaev SA, Dong YY, Abbott MA, Asteggiano C, et al. Predominant and novel de novo variants in 29 individuals with ALG13 deficiency: clinical description, biomarker status, biochemical analysis, and treatment suggestions. Journal of Inherited Metabolic Disease. 2020; 43: 1333–1348.

[38] De Antonellis P, Carotenuto M, Vandenbussche J, De Vita G, Ferrucci V, Medaglia C, et al. Early targets of miR-34a in neuroblastoma. Molecular & Cellular Proteomics. 2014; 13: 2114–2131.

[39] Nie G, Luo L, Duan H, Li X, Yin M, Li Z, et al. GALNT7, a target of miR-494, participates in the oncogenesis of nasopharyngeal carcinoma. Tumor Biology. 2016; 37: 4559–4567.

[40] Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005; 69: 4–10.

[41] Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology. 2005; 23: 1011–1027.

[42] Mirzaei A, Rashedi S, Akbari MR, Khatami F, Aghamir SMK. Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes. Journal of Cellular and Molecular Medicine. 2022; 26: 2728–2740.

[43] Zhang J, Zhang G, Zhang W, Bai L, Wang L, Li T, et al. Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer. Cell Death & Differentiation. 2022; 29: 2247–2261.

[44] Chen Y, Su L, Huang C, Wu S, Qiu X, Zhao X, et al. Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11p110. Cancer Letters. 2021; 500: 228–243.

[45] Schömel N, Hancock SE, Gruber L, Olzomer EM, Byrne FL, Shah D, et al. UGCG influences glutamine metabolism of breast cancer cells. Scientific Reports. 2019; 9: 15665.

[46] Schömel N, Gruber L, Alexopoulos SJ, Trautmann S, Olzomer EM, Byrne FL, et al. UGCG overexpression leads to increased glycolysis and increased oxidative phosphorylation of breast cancer cells. Scientific Reports. 2020; 10: 8182.